openPR Logo
Press release

Tardive Dyskinesia Treatment Market to Register a Stout Growth by End 2025

05-16-2018 07:07 PM CET | Health & Medicine

Press release from: Transparency Market Research

Tardive Dyskinesia Treatment Market to Register a Stout Growth

Tardive dyskinesia (TD) is a disorder caused by a prolonged use of antipsychotic drugs by patients suffering from schizophrenia and other neuroleptic disorders. It is characterized by involuntary and uncontrolled movements of body parts such as eyeballs, lips, and tongue. Although tardive dyskinesia commonly occurs in patients who have been treated with antipsychotic medication for long periods, it also occurs occasionally in other conditions such as fetal alcohol syndrome, developmental disabilities, and other brain disorders, even after receiving 1 dose of causative agent. However, there are new atypical antipsychotic agents, such as olanzapine and risperidone, which have lesser risk of developing tardive dyskinesia.

The disorder is linked with polymorphism of dopamine receptor gene types. The commonly used antipsychotic agents that are associated with tardive dyskinesia are chlorpromazine (Thorazine), fluphenazine (Prolixin), haloperidol (Haldol), thioridazine (Mellaril), and trifluoperazine (Stelazine). The risk of developing tardive dyskinesia is higher in older patients, women, and African & African-American population receiving antipsychotic treatment. It is estimated that approximately 500,000 people in the U.S. are affected by tardive dyskinesia each year. Increasing incidences of schizophrenia, growing bipolar disorder patients, and increasing antipsychotic prescriptions are driving the Tardive Dyskinesia Treatment Market. However, side effects of drugs, lack of awareness about the disorder and its medication, and undiagnosed cases are restricting the market growth.

The global tardive dyskinesia treatment market can be segmented based on type of disorder, drug class, and region. Based on the type of disorder, the market can be segmented as bradykinesias and hyperkinesias. Bradykinesias involves slowing of motion and difficulty in starting any action whereas hyperkinesias is characterized by akathisia, chorea, dystonia, myoclonus, stereotypy, tic, and tremor. Based on drug class, the market is segmented as dopamine-depleting medications (e.g., tetrabenazine, reserpine, and amantadine), GABA receptor agonist medications (e.g., clonazepam, baclofen, and valproic acid), and anticholinergic medications (e.g., trihexyphenidyl). In 2017, the FDA approved valbenazine (Ingrezza) for the treatment of adults with tardive dyskinesia. Ingrezza is manufactured by Neurocrine Biosciences, Inc, which is the first approved therapy for the treatment of the disorder.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28283

In addition, a variety of medicines are used for the treatment of tardive dyskinesia such as clonidine; however, dose limiting hypotension and sedation are its restraining factors. Botox injections are tried for minor dystonia. Vitamin B6, vitamin E, and branched chain amino acids are reported to be helpful to minimize the symptoms of the disorder. Benzodiazepine (clonazepam) is an effective therapy for tardive dyskinesia, however the development of tolerance is limiting its market growth. TEVA’s Austedo was approved for the treatment of chorea associated with Huntington’s disease; however, it is also filed for the new indication, which is for the treatment of tardive dyskinesia. Austedo is likely to create competition for Neurocrine Biosciences' Ingrezza.

Geographically, the tardive dyskinesia treatment market is distributed over North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is leading the market due to high prevalence of schizophrenia, increasing health awareness, and growing research and development investment. Middle East & Africa is the second largest market after the U.S., followed by Europe. The market in Asia Pacific is expected to grow with a decent pace during the forecast period due to increasing health awareness and growing number of schizophrenic, bipolar, and other neuroleptic disorder patients.

Key players operating in this market are Neurocrine Biosciences, Teva Pharmaceutical Industries, Valeant Pharmaceuticals, Sterimax Inc, Sun Pharma Global FZE, Pharmascience Inc., Eon Labs, Inc., Novopharm Limited, Novartis, and Oceanside Pharmaceuticals.

View Report -

https://www.transparencymarketresearch.com/tardive-dyskinesia-treatment-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tardive Dyskinesia Treatment Market to Register a Stout Growth by End 2025 here

News-ID: 1052189 • Views: 370

More Releases from Transparency Market Research

Fuel Dispenser Market - Global Industry Analysis, Size, Share, Growth, Trends, a …
Albany, NY - Fuel Dispenser Market: Introduction In terms of value, the global fuel dispenser market is expected to reach ~US$ 2 Bn by 2030, expanding at a CAGR of ~4% during the forecast period. Based on volume, the global fuel dispenser market is estimated to reach 662,058 units by 2030, expanding at a CAGR of ~4% during the forecast period. In terms of type, the submersible system segment holds leading
Brazil Flavored and Functional Water Market Outlook, Gains Traction, Analysis An …
According to the report, the market will exhibit an impressive CAGR of 7.3% during the projection period. With this rate of growth, by the end of 2024, the market will be valued around US$9.4 bn. It is a considerable growth from the initial valuation recorded at US$5 bn in 2015. A new report by Transparency Market Research expects the Brazil flavored functional water market to grow at considerable pace over
Advantame Market Trends , Incredible Growth Opportunities, Volume, Value Growth …
Increasing health issues among the population led to an increase in the demand for non-caloric sweetener. In the global food and beverage market, the demand for advantame is on rising owing to its non-caloric sweetener properties. Advantame is one of the most recent, high potency low-calorie sweeteners to arrive in the food and beverage market with clean sugar-like the taste. The rising consumption of unhealthy/ comfort sugary food with high calories
Trends in the Feed ingredients - Outlook, Share and Opportunities in Grooming Re …
Escalating demand for high nutritional value meat is one of the major factor driving the growth of global feed ingredients market. In the global meat products market, safety is one of the major concern among meat manufacturers owing to stringent rules laid by government organizations during the handling, procurement, processing, storage, and distribution of animal products. The inclusion of high nutritive value feed ingredient into animal feed results in more

All 5 Releases


More Releases for Tardive

Antioxidants May Aid in the Treatment of Tardive Dyskinesia
Memphis, TN (May 9, 2019) – Today, The Primary Care Companion for CNS Disorders published a case report on the use of antioxidants in the treatment of tardive dyskinesia. While new pharmacologic discoveries have occurred in the area of movement disorders, their use comes with a large price tag. Thus, for mild cases, clinicians may want to seek out more cost-effective options. Antioxidants may serve a role in the prevention
Tardive Dyskinesia (TD) Treatment Market Worldwide Industry Analysis and New Mar …
Tardive dyskinesia is a type of neurological disorder, which characterized the blink your eyes fast, chew, smack or pucker of lips, puff out your cheeks, tongue and others. The patients treating with neuroleptic drugs or anti-psychotic medications can also be the cause of tardive dyskinesia. Tardive dyskinesia is difficult to treat as treatment process is also not confirmed and the drug is also not approved in various conditions.
Tardive Dyskinesia (TD) Treatment Market - Competitive Dynamics and Global Indus …
Tardive dyskinesia is a type of neurological disorder, which characterized the blink your eyes fast, chew, smack or pucker of lips, puff out your cheeks, tongue and others. The patients treating with neuroleptic drugs or anti-psychotic medications can also be the cause of tardive dyskinesia. Tardive dyskinesia is difficult to treat as treatment process is also not confirmed and the drug is also not approved in various conditions.
Tardive Dyskinesia (TD) Treatment Market Forcasted for Accelerated Growth by 202 …
Global Tardive Dyskinesia (TD) Treatment Market: Overview Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging, repetitive chewing, continuous blinking of the eyes, tongue thrusting, and others. The side effect of the neuroleptics medicines is tardive dyskinesia.
Tardive Dyskinesia (TD) Treatment Market grows with high prevalence of schizophr …
Tardive dyskinesia (TD) is a disorder caused by a prolonged use of antipsychotic drugs by patients suffering from schizophrenia and other neuroleptic disorders. It is characterized by involuntary and uncontrolled movements of body parts such as eyeballs, lips, and tongue. Although tardive dyskinesia commonly occurs in patients who have been treated with antipsychotic medication for long periods, it also occurs occasionally in other conditions such as fetal alcohol syndrome, developmental
Tardive Dyskinesia Drugs Market
Tardive dyskinesia (TD) is a form of dyskinesia that is difficult to treat. It is a nerve disorder characterized by involuntary movements such as jaw, lips, and tongue, considered as grimacing, sticking the tongue out, and lip smacking. Some other symptoms are an individual experiencing involuntary movement of the lower and upper extremities and also breathing choking. According to Center for Drug Evaluation and Research, tardive dyskinesia can lead to